

Drug and Therapeutics Committee – Minutes – Confirmed

Date / Time	Thursday 11 th January 2018 8:15am – 9.30am
Venue	The Committee Room, Alderson House, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs Susan Greene, Senior Pharmacy Technician (SG)
Quorate: Yes / No	Yes

Attendance	Mr S P Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services (SPG) Prof M Lind, Vice Chair, Professor of Oncology Dr O Ogunbambi, Consultant Rheumatologist Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Mr P O'Brien – Deputy Chief Pharmacist Dr H Klonin, Consultant Paediatrician Dr A Samson, Infectious Diseases Consultant Mr R Kapur, Vascular Surgeon Mrs E Lyle, Locality Pharmacist, Medicines Management, Hull NECS (deputy for KMcC)
-------------------	--

Apologies	Mr K McCorry, Medicines Management, East Riding
------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2018.01.01	Apologies	As above.					
2018.01.02	Declarations of Interest	AM declared he had been a speaker for Chiesi (manufacturer of Trimbow).	Noted				01/18
2018.01.03	Minutes of the previous meeting	The minutes were accepted as a true record.					
2018.01.04	Action Tracker	<p>Bisphosphonates as supportive therapy for Breast Cancer ML had produced a summary paper of the situation. SG would circulate this for information after the meeting. The drugs involved were already on the formulary. It was felt that this should be guideline lead, so a HERPC guideline was now needed - for further discussion at HERPC. Cancer Pharmacist team to help produce a HERPC guideline. POB to brief Sarah Scargill (SS), as lead Pharmacist.</p> <p>Tedizolid Report SG had updated and circulated the D&TC new product request form – this was approved for use from now. It now includes a section for how the drug will be funded, in addition to the cost.</p> <p>Argatroban Injection POB had liaised with the renal Pharmacist. The Trust has a policy of only using a single vial per patient, which will be a significant cost. The renal team were currently writing guidance on when and how the product would be used.</p> <p>Ixekizumab (Taltz) Pre filled Syringe/Pen Ann Kristensen has a meeting arranged with Colin Vize to discuss issues and ensure use is in line with commissioning.</p> <p>Rivaroxaban (Xarelto) Initiation Pack This has been added to the agenda for next SMPC meeting.</p>	<p>Ongoing</p> <p>Action complete. New product request form approved.</p> <p>Action complete.</p> <p>Action complete.</p> <p>Action complete.</p>	<p>ML/SS to write guideline for HERPC</p> <p>SG to add updated form to Pattie</p>	<p>ML</p> <p>SG</p>	<p>01/18</p> <p>02/18</p>	<p>01/18</p> <p>01/18</p> <p>01/18</p> <p>01/18</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>Tofacitinib for moderate to severe rheumatoid arthritis Clinical pathway is being written, in conjunction with Emily Hardaker, Senior Pharmacist for Rheumatology.</p> <p>Imuderm letter – Dr R Zaman SG had updated formulary.</p> <p>Cladribine tablets AM had written to all applicants and SG had updated the formulary.</p> <p>Regorafenib (Stivarga) Caps 40mg SG had added to formulary</p> <p>Flamigel and Flaminal Hydro SG had added both to the formulary for Radiotherapy use only.</p> <p>Tofacitinib (Xeljanz) SG had added to the formulary and MMIG agenda.</p> <p>Nivolumab for previously treated squamous non-small-cell lung cancer NICE TA483 SG had added to the CDF list.</p> <p>Nivolumab for previously treated non-squamous non-small-cell lung cancer NICE TA484 SG had added to the CDF list.</p> <p>Sarilumab for moderate to severe rheumatoid arthritis NICE TA485 OO to arrange a new product request.</p> <p>Venetoclax for treating chronic lymphocytic leukaemia NICE TA487 SG had added to the CDF list.</p> <p>Vismodegib for treating basal cell carcinoma NICE TA489 SG had removed this from the formulary CDF list.</p>	<p>Clinical Pathway to be completed</p> <p>Action complete.</p> <p>Actions complete.</p> <p>Action complete.</p> <p>Action complete.</p> <p>Action complete.</p> <p>Action complete.</p> <p>Action complete.</p> <p>Ongoing</p> <p>Action complete.</p> <p>Action complete.</p>	<p>OO to prepare pathway for next D&TC</p> <p></p> <p></p> <p></p> <p></p> <p></p> <p></p> <p>OO to arrange</p> <p></p> <p></p>	<p>OO</p> <p></p> <p></p> <p></p> <p></p> <p></p> <p>OO</p> <p></p> <p></p>	<p>01/18</p> <p></p> <p></p> <p></p> <p></p> <p></p> <p>02/18</p> <p></p> <p></p>	<p></p> <p>01/18</p> <p>01/18</p> <p>01/18</p> <p>01/18</p> <p>01/18</p> <p>01/18</p> <p></p> <p>01/18</p> <p>01/18</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy TA490 SG had added to the CDF list.</p>	Action complete.				01/18
		<p>Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane NICETA458 SG had moved this from the CDF list onto the formulary.</p>	Action complete.				01/18
		<p>Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma NICE TA462 ML had asked for new product request.</p>	Action complete.				01/18
		<p>Gentamicin: potential for histamine-related adverse drug reactions with some batches AS had liaised with Dr Barlow and POB had forwarded the alert. Information had been circulated around the Trust.</p>	Action complete.				01/18
		<p>Tolvaptan guideline SG had added to the agenda for discussion at this meeting.</p>	Action complete.				01/18
		<p>What happens when you are referred by your GP to see a specialist? leaflet SPG had circulated this to the committee.</p>	Action complete.				01/18
		<p>Opicapone AM had written to applicant and SG had added to the formulary.</p>	Actions complete.				01/18
		<p>Terms of reference for D&TC SG had added frequency of attendance to the OQC escalation form for discussion and DC had raised it at the meeting. OQC agreed that the expected attendance by clinicians could be reduced from 10 out of 12 meetings, to 9 out of 12 meetings.</p>	Action complete. SPG to update D&TC ToR.	SPG to update ToR	SPG	02/18	01/18
		<p>Pharmacy – excellent service – HK DC had fed back to the relevant staff involved</p>	Action complete.				01/18
		<p>Coroner’s Regulation 28 report to prevent future deaths –</p>					

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>death of a chronic IV opiate abuser SPG had circulated the report.</p> <p>Drug company advertising on the HEY Pattie Intranet DC had fed back to MC. DC had been asked to bring the issue back to the meeting, as other Trusts have this in place, without contradicting Trust guidelines. They also stated that it can be set up to target an audience, rather than for all users.</p> <p>Gadolinium Contrast Agents MHRA letter The affected agents were not listed on the formulary document, so no further action was required.</p>	<p>Action complete.</p> <p>Action complete. DC to obtain more information, or invite someone to D&TC.</p> <p>Action complete.</p>	<p>DC to contact Bonnie Gray</p>	<p>DC</p>	<p>02/18</p>	<p>01/18</p> <p>01/18</p> <p>01/18</p>
2018.01.05	New Product Requests	<p>Etelcalcetide injection – Dr A Syed Approved in line with NICE TA448, for secondary hyperparathyroidism in adult patients with chronic kidney disease on haemodialysis.</p> <p>Eluxadoline tablets – Dr G Abouda Approved in line with NICE TA471, for irritable bowel syndrome with diarrhoea in adults. Would probably need a HERPC guideline to support use as per NICE.</p> <p>Pure fructose (for hydrogen breath testing) – S Hewitt Approved to establish if a patient is fructose intolerant. POB to ask Pharmacy purchasing department to find a suitable quality product.</p> <p>Trimbow MDI – Dr M Crooks Approved for patients with moderate to severe COPD, who require combined inhaled ‘triple therapy’ with a long acting muscarinic receptor antagonist (LAMA), long acting beta-2 adrenoceptor agonist (LABA) and inhaled corticosteroid (ICS).</p> <p>Baricitinib (Olumiant) tablets – Dr O Ogunbambi Approved in line with NICE TA466 for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have</p>	<p>Approved.</p> <p>AM to write to all applicants.</p> <p>Approved.</p> <p>Approved subject to sourcing quality product.</p> <p>Approved.</p> <p>Approved.</p>	<p>POB to check funding AM to write</p> <p>POB to arrange a source</p> <p>AM to update HERPC COPD guideline to include it</p> <p>SPG to ensure the request form</p>	<p>POB</p> <p>AM</p> <p>POB</p> <p>AM</p> <p>SPG</p>	<p>02/18</p> <p>02/18</p> <p>02/18</p> <p>03/18</p> <p>02/18</p>	<p>01/18</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs. Can be used as monotherapy or in combination with methotrexate.		is signed			
2018.01.06	Guidelines	<p>Guidelines for the use of a High Fibre Supplement to prevent Constipation in Peritoneal Dialysis – Sue Perry, Dietician Optifibre is recommended in this guideline, but is not on the HEY formulary. This is a borderline substance and questions were asked about supply, as it was not listed in the Drug Tariff for PD or constipation. SPG was asked to contact the author for further information.</p> <p>Hull And East Yorkshire Hospitals NHS Trust Guidelines on the Prescribing of Tolvaptan – M Miller This had been updated to include NICE TA358.</p>	<p>Deferred. More information needed on how this would be prescribed or supplied.</p> <p>Approved.</p>	<p>SPG to contact Sue Perry</p> <p>AM to write to author</p>	<p>SPG</p> <p>AM</p>	<p>02/18</p> <p>02/18</p>	
2018.01.07	Correspondence received	<p>Implementing specialised services circulars – NHSE, 19/12/17 Notification had been received from NHSE that from 01/01/18, providers would need to notify them of their intention to use a new intervention/treatment before pass through charges would be accepted. This would include estimated numbers in the first year and confirmation that the Trust will be compliant with the circular – including Blueteq registration. DC informed the committee that he and POB would be taking this forward, with a 01/02/18 start date. This linked well with the new product request form approved earlier, which asked the applicant about patient numbers, cost and funding arrangements. DC would also escalate this NHSE notification to OQC.</p> <p>Freestyle Libre – Dr B Allen, 20/12/17 Dr Allen had emailed to ask if Freestyle Libre Flash Glucose Monitoring (FGM) system would require a D&TC new product request. As this was not a drug, it was felt this was not necessary. The technology was supported by NICE MIB110 and there was already an ER CCG general commissioning policy on it. This stated that it would be regarded like a RED drug, for hospital specialist prescribing/supply only, with recharge to CCG. SPG was asked to feed back.</p>	<p>DC & POB are implementing.</p> <p>Use approved, in line with NICE and CCG position.</p>	<p>DC to escalate to OQC</p> <p>SPG to feed back to Dr Allen. Dr Allen to work with Endocrinology Senior Pharmacists on supply process</p>	<p>DC</p> <p>SPG</p>	<p>02/18</p> <p>02/18</p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2018.01.08	NICE Guidance December 2107	<p>Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable https://www.nice.org.uk/guidance/ta492</p> <p>Cladribine tablets for treating relapsing–remitting multiple sclerosis https://www.nice.org.uk/guidance/ta493</p> <p>Naltrexone–bupropion for managing overweight and obesity https://www.nice.org.uk/guidance/ta494 - not recommended</p> <p>Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer https://www.nice.org.uk/guidance/ta495</p> <p>Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer https://www.nice.org.uk/guidance/ta496</p> <p><u>Updates:</u> Autism spectrum disorder in under 19s: recognition, referral and diagnosis https://www.nice.org.uk/guidance/cg128</p>	<p>Not on formulary.</p> <p>On formulary.</p> <p>Combination is not on formulary.</p> <p>On formulary.</p> <p>Not on formulary.</p> <p>Noted.</p>	<p>ML to request application from Dr Butt</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>ML to request application</p> <p>No further action</p>	<p>ML</p> <p></p> <p></p> <p>ML</p> <p></p>	<p>02/18</p> <p></p> <p></p> <p>02/18</p> <p></p>	<p></p> <p>01/18</p> <p>01/18</p> <p>01/18</p> <p></p> <p>01/18</p>
2018.01.09	MHRA Drug Safety Update December 2017	<ul style="list-style-type: none"> Gadolinium-containing contrast agents: removal of Omniscan and iv Magnevist, restrictions to the use of other linear agents Cladribine (Litak, Leustat) for leukaemia: reports of progressive multifocal encephalopathy (PML); stop treatment if PML is suspected Radium-223 dichloride (Xofigo ▼): do not use in combination with abiraterone and prednisone/prednisolone following clinical trial signal of increased risk of death and fractures Eluxadoline (Truberzi ▼): risk of pancreatitis; do not use in patients who have undergone cholecystectomy or in those with 	<p>Noted</p> <p>Noted</p> <p>Noted</p> <p>Noted. New drug approved above today.</p>	<p>No further action</p> <p>No further action</p> <p>No further action</p> <p>AM to include in letter to applicant</p>	<p></p> <p></p> <p></p> <p>AM</p>	<p></p> <p></p> <p></p> <p>02/18</p>	<p>01/18</p> <p>01/18</p> <p>01/18</p> <p></p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		biliary disorders <ul style="list-style-type: none"> Fingolimod (Gilenya ▼): new contraindications in relation to cardiac risk Fingolimod (Gilenya ▼): updated advice about risk of cancers and serious infections 	Noted	No further action			01/18
			Noted	No further action			01/18
2018.01.10	Minutes from the Safe Medication Practice Committee	November 2017 (DRAFT) DC highlighted that electronic prescribing was in place on C29, with lots of ongoing work before it could be rolled out further at QCOH. It is hoped that by the end of May more QCOH wards will be using it.	Noted	No further action			01/18
2018.01.11	Minutes from the Hull and East Riding Prescribing Committee	September 2017 (Confirmed) The contents were noted.	Noted	No further action			01/18
2018.01.12	Regional Medicines Optimisation Committee	The following document link was attached for information: https://www.sps.nhs.uk/wp-content/uploads/2017/06/RMOC-minutes-June-28th-2017.pdf This was the most recent document on the website.	Noted.	No further action			01/18
2018.01.13	Chairs approvals	Zanamivir IV - Dr P Lillie Influenza virus treatment for a severely unwell patient on HICU1 that was deteriorating and was no-longer absorbing oral oseltamivir. Zanamivir is on the formulary, but the IV formulation was supplied as an unlicensed medicine by the manufacturer. Use was in line with the PHE national guidance on influenza.	Noted	No further action			01/18
2018.01.14	Issues to escalate to Operational Quality Committee	Implementing specialised services circulars - NHSE As above at 2018.01.07, DC would escalate the NHSE notification about implementing specialised services circulars to OQC.	Action as above				01/18
2018.01.15	Any Other	Pregnyl hCG discontinuation					

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
	Business	This product had been discontinued. POB was discussing alternatives with the clinicians who use the product, as to the most appropriate alternative.					
	Date and Time of Next Meeting	Date and Time of Next Meeting Date – Thursday 8th February 2018 Time - 8.15am - 9.30am Venue – Committee Room, Alderson House, HRI					